Clinical Trials Browser

Phase EARLY_PHASE1 × daratumumab × 90 days × Clear all

NCT04139304 2026-06-01

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Phase EARLY_PHASE1 Recruiting

Plasmablastic Lymphoma